Related Experiment Video
Updated: Mar 26, 2026
Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
Published on: July 16, 2018
Targeting glioblastoma stem cells (GSCs) with peroxisome proliferator-activated receptor gamma (PPARγ) ligands
Chang-Nim Im1,2,3
1Department of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul.
Abstract:
Glioblastoma multiforme (GBM), also known as glioblastoma, is the most common and aggressive brain tumor. GBM has a poor survival rate and high resistance to standard therapy, leading to recurrence and metastasis to adjacent normal regions. Glioblastoma stem cells (GSCs) are regarded as an emerging target for therapy of GBM. Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor that functions in a variety of cancers and in normal adipocyte differentiation. The newly discovered connection between PPARγ ligands and cancer stem cells (CSCs) raises important implications for the potential therapeutic use of synthetic PPARγ ligands, such as thiazolidinediones (TZDs), in glioblastoma. Here, I hypothesize that synthetic PPARγ ligands serve to modulate stemness-related molecules and several signaling pathway in GSCs and I propose potential experimental approaches to investigate the effects of these ligands on GSCs in vitro and in vivo.
Insights
Synthetic PPARγ ligands may offer a new glioblastoma treatment by targeting glioblastoma stem cells (GSCs). These compounds, like thiazolidinediones (TZDs), could modulate stemness pathways, offering hope against aggressive brain tumors.
Area of Science:
- Neuro-oncology
- Molecular biology
- Cancer stem cell research
Background:
- Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor prognosis.
- Glioblastoma stem cells (GSCs) are key drivers of GBM recurrence and treatment resistance.
- Peroxisome proliferator-activated receptor gamma (PPARγ) is implicated in cancer and adipocyte differentiation.
Purpose of the Study:
- To investigate the therapeutic potential of synthetic PPARγ ligands in targeting GSCs.
- To explore the role of PPARγ ligands in modulating stemness pathways within GSCs.
- To propose experimental strategies for evaluating PPARγ ligands in GBM treatment.
Main Methods:
- Hypothesize modulation of stemness-related molecules and signaling pathways in GSCs by PPARγ ligands.
- Propose in vitro and in vivo experimental approaches to study ligand effects on GSCs.
- Focus on synthetic PPARγ ligands, including thiazolidinediones (TZDs).
Main Results:
- The study hypothesizes that synthetic PPARγ ligands can modulate key pathways in GSCs.
- PPARγ ligands may offer a novel therapeutic strategy by targeting cancer stem cells.
- The connection between PPARγ ligands and cancer stem cells (CSCs) suggests therapeutic implications.
Conclusions:
- Synthetic PPARγ ligands represent a promising avenue for glioblastoma therapy.
- Targeting GSCs with PPARγ ligands could overcome treatment resistance in GBM.
- Further research is warranted to elucidate the mechanisms and efficacy of PPARγ ligands in glioblastoma.
More Related Videos
10:28Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
Published on: January 10, 2018
09:44Imaging Glioma Initiation In Vivo Through a Polished and Reinforced Thin-skull Cranial Window
Published on: November 20, 2012
